<DOC>
	<DOCNO>NCT00087789</DOCNO>
	<brief_summary>This Phase I clinical study ass safety , tolerability biologic activity vivo AAV-mediated delivery CERE-110 . Up 12 subject receive open label CERE-110 dose-escalating fashion . All subject receive bilateral , stereotactic injection CERE-110 total four ( Dose A B ) six ( Dose C ) injection target basal forebrain region brain contain nucleus basalis Meynert ( NBM ) . All study participant observe 24-month period follow annually .</brief_summary>
	<brief_title>CERE-110 Subjects With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Alzheimer 's disease determine NINCDS/ADRDA criterion . Score ≤ 4 modify Hachinski Ischemia Scale MiniMental State Exam ( MMSE ) score range 16 28 , inclusive No significant neurological medical abnormality contraindicate surgery , MRI/PET image study participation Subjects stable standardofcare medication ( i.e. , acetylcholinesterase inhibitor ) Alzheimer 's disease 3 month prior entry A Hamilton Depression Scale score ≤ 12 17item scale history major depressive episode within last 2 year A score &lt; 15 Beck Depression Inventory Adequate visual auditory acuity allow neuropsychological test Good health clinically significant medical psychological condition An MRI head screen negative evidence infection , tumor , infarction focal ( e.g. , subdural hematoma ) generalize lesion ( e.g. , v hydrocephalus ) without clinical symptom suggestive intervene neurological disease Normal serum B12 , thyroid function test , negative syphilis antibody test The informed consent document must sign : competent willing subject , surrogate identify participant , legally authorize power attorney Health Care , family member History cancer within last five year , except superficial basal squamous cell skin cancer cervical carcinoma situ History alcohol abuse dependence within last two year Liver serum transaminase ( AST and/or ALT ) &gt; 5 time upper limit normal ; total and/or direct bilirubin &gt; 1.5 mg/dL , hemoglobin &lt; 9mg/dL ; PT PTT &gt; 2 time upper limit normal ; creatinine clearance &lt; 30 mL/min ; positive serology HBV HCV ; absolute neutrophil count &lt; 1,500 cells/mm3 platelet count &lt; 100,000/mm3 Any significant systemic illness , unstable severe medical condition ( ) could put subject risk study , interfere outcome measure affect compliance protocol procedure Centrally active betablockers , antiParkinsonian medication , psychostimulants , antipsychotic , neuroleptic , narcotic analgesic , longacting benzodiazepine barbiturate , hypertensive agent CNS effect , shortacting anxiolytic sedative hypnotic frequently two time per week within 14 day screen , herbal product Alzheimer 's disease , antidepressants significant cholinergic side effect ( e.g. , tricyclic ) , initiation change dose standard treatment Alzheimer 's disease Other medication significant cholinergic anticholinergic side effect Warfarin ( coumadin ) , nonsteroidal antiinflammatory drug , aspirin , Prozac , Ginkgo biloba within 14 day surgery Subjects receive investigational agent expose investigational device 30 day prior enrollment Subjects history receive gene transfer product kind Subjects undergo MRI PET screen</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Gene Transfer</keyword>
</DOC>